ClinicalTrials.gg
Active, not recruitingNCT07197905Updated Nov 9, 2026

Restoring Iron Deficiency in POTS

A Phase 2 interventional study of Intravenous iron in POTS - Postural Orthostatic Tachycardia Syndrome, sponsored by Vanderbilt University Medical Center. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Vanderbilt University Medical Center · Phase 2, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center — 2 open to participants now, 13 under way, none of them phase 3. Postural Orthostatic Tachycardia Syndrome · Vanderbilt University Medical Center.

Planned enrollment
12th of 13
12 · median 40
Started
2025
with 1 other
Phase 2
3 of 18
2 open now
Primary completion
2026-12
later than 5 of 12 live
Registered
18th of 18
by date

Among the 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center, this one is the 12th largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 in phase 2, reaches primary completion later than 5 of the 12 other live ones, and was the 18th registered.

Postural Orthostatic Tachycardia Syndrome

136 studies on the registry are indexed under Postural Orthostatic Tachycardia Syndrome; 42 are open to participants now.

Browse Postural Orthostatic Tachycardia Syndrome studies →

Open to participants now

2 of the 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 29 Postural Orthostatic Tachycardia Syndrome studies recruiting now, 9 (31%) set no upper age limit and 16 (55%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Postural Orthostatic Tachycardia Syndrome by Vanderbilt University Medical Center, or all of them as a file.
02

Study summary

People with postural orthostatic tachycardia syndrome (POTS) often have low red blood cell volumes and low ferritin in their blood (a marker of iron storage in the body). The purpose of this pilot study is to investigate whether giving iron to people with POTS who have low ferritin levels will increase the red blood cell volume and improve POTS symptoms.

Read the detailed description

This pilot study involves undergoing a physical exam and medical history, answering some questionnaires, and visiting the Vanderbilt Autonomic Dysfunction Center before and 2 months after the iron treatment for bloodwork, blood volume measurements, autonomic function tests, and wearing an activity monitor.

03

Conditions studied

  • POTS - Postural Orthostatic Tachycardia Syndrome

Keywords

  • Postural Tachycardia Syndrome
  • Iron Deficiency
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-45 years old.
  • Diagnosis of POTS, defined by a sustained heart rate increase of at least 30 bpm within 10 min of standing or head-up tilt (or absolute upright heart rate >120 bpm), in the absence of orthostatic hypotension, and with at least 3 months of symptoms of orthostatic intolerance.
  • Absence of other diseases or medications that can explain orthostatic tachycardia or symptoms.
  • Serum ferritin \<50 ng/ml.
  • Patients on fludrocortisone will be allowed to participate as long as they have been on the same dose for at least one month before enrollment and continue on the same dose throughout the study.

Exclusion criteria

Exclusion Criteria

  • Unable or unwilling to provide consent.
  • Pregnancy.
  • Being chair- or bed-ridden.
  • Unable to hold POTS medications during study procedures (i.e., autonomic testing).
  • History of active bleeding (other than menstruation).
  • History of to any iron preparation of recent (within 6 months) treatment with any IV iron preparation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Intravenous Iron Infusion

    The Intravenous iron infusion will be administered according to standard clinical care.

    Drug: Intravenous iron

Interventions

  • DrugIronStudies of IronIron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The Intravenous iron infusion will be administered according to standard clinical care. The provider will choose the dosage and formulation of IV iron.

06

What researchers measure

Primary outcomes

  1. Orthostatic tachycardia

    Orthostatic tachycardia, defined as the difference between upright and supine heart rates, will be assessed during a 10-minute head-up tilt test.

    Time frame: Orthostatic tachycardia will be assessed before iron infusion (Visit 1) and after 2 months of treatment (Visit 2)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Oct 2026 → Dec 2026 and completion Dec 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Sep 30, 2025
StartActual
Nov 24, 2025
Primary completionEst.
Dec 2026was Oct 2026
CompletionEst.
Mar 2027was Dec 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 13, 2026
Primary completion
Oct 2026→Dec 2026
Nov 9, 2026
Study completion
Dec 2026→Mar 2027
Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    Primary completion Oct 2026→Dec 2026
    Study completion Dec 2026→Mar 2027
    + 1 other change: verification date
  2. Oct 13, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07197905
Collaborators
Dysautonomia International
Responsible party
Italo Biaggioni (Professor of Medicine and Pharmacology, Vanderbilt University Medical Center) — Principal investigator
First posted
Sep 30, 2025
Start date
Nov 24, 2025
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

Italo Biaggioni, MD
principal investigator · Vanderbilt University Medical Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iron

Start the discussion